Resilience of individuals with familial hypercholesterolaemia to develop atherosclerotic cardiovascular disease: lessons learned from the elderly
- PMID: 34864977
- DOI: 10.1093/eurjpc/zwab196
Resilience of individuals with familial hypercholesterolaemia to develop atherosclerotic cardiovascular disease: lessons learned from the elderly
Conflict of interest statement
Conflict of interest: R.D.S. has received honoraria for consulting, speaker activities and research from Abbott, Ache, Amgen, Amryt, Astra Zeneca, EMS, Hypera, Libbs, Esperion, Kowa, Getz pharma, PTC therapeutics, Novo-Nordisk, Novartis, Merck, MSD, Pfizer, Roche, and Sanofi. E.R.C. has received honoraria for speaker activities for Amgen and Novartis.
Comment on
-
A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort.Eur J Prev Cardiol. 2022 May 5;29(5):795-801. doi: 10.1093/eurjpc/zwab185. Eur J Prev Cardiol. 2022. PMID: 34864959
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical